Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (1) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: A feeding and blending apparatus for a system for continuous processing of powder products comprises at least two system inlets for powder products; and at least two feeding and dosing devices arranged in a row. Each of the at least two feeding and dosing devices comprises, an inlet being connected with a system inlet, at least one feeder, at least one actuator configured to operate the at least one feeder, and an outlet being connected with an inlet of the powder blending device. A separation wall is configured to separate a process area from a technical. Process components of the at least two feeding and dosing devices are positioned in the process area and technical components of the feeding and dosing devices are positioned in the technical area. Connections between the at least one actuator and the at least one feeder pass through the separation wall.

Abstract: A powder blender for a system for continuous processing of powder products comprises a horizontal blending tube extending along an axis from a first end to a second end. The horizontal blending tube comprises at least one inlet configured to receive the powder products to be blended, and at least one outlet configured to discharge the powder products after blending. At least two blending devices are positioned in the blending tube and arranged successively along the axis of the blending tube. At least two actuators, wherein each of the at least two actuators is configured to operate one of the at least two blending devices such that the at least two blending devices are actuated differently from each other.

Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).

Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).

Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: An oil-injected vacuum pump element, where two mating helical rotors are rotatably provided in a housing, where this housing includes an inlet port and an outlet end face with an outlet port, where compression chambers are formed between the helical rotors and the housing. The vacuum pump element is provided with a connection that extends from a first compression chamber to a second smaller compression chamber at the outlet end face, where this first compression chamber is at a lower pressure than the second compression chamber and where this second compression chamber can make connection with the outlet port upon rotation of the helical rotors, where the connection is such that a flow from the second compression chamber to the first compression chamber is possible, where the connection is not directly connected to the outlet port.

Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).

Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: Systems, methods, and computer program products for performing account reconciliation over a computer network. The system comprises means for receiving an invoice, an actual sales database, and a reconciliation network platform. The reconciliation network platform processes the supplier invoice to extract and store the corresponding SII data in a set of SII records. A reconciliation module is provided for selecting, based on at least one Reconciliation Criterion, SII records and ASI records for reconciliation. The reconciliation module is configured for aggregating and storing, for each Reconciliation Criterion, the values of the selected SII and ASI records into a set of corresponding data fields of a Reconciliation Item Record. The reconciliation module further compares the aggregated values of the corresponding data fields of the Reconciliation Item Record and determines a reconciliation status.

Abstract: An oil-injected vacuum pump element, whereby two mating helical rotors are rotatably provided in a housing, whereby this housing comprises an inlet port and an outlet end face with an outlet port, whereby compression chambers are formed between the helical rotors and the housing, wherein the vacuum pump element is provided with a connection that extends from a first compression chamber to a second smaller compression chamber at the outlet end face, whereby this first compression chamber is at a lower pressure than the second compression chamber and whereby this second compression chamber can make connection with the outlet port upon rotation of the helical rotors, whereby the connection is such that a flow from the second compression chamber to the first compression chamber is possible, whereby the connection is not directly connected to the outlet port.

Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: A method for continuous production of tablets, including providing a contained module comprising at least two inlets, at least one mixing unit, at least one analytical sensor, a tablet press, and at least one outlet for tablets, feeding an active pharmaceutical ingredient (API) to one of the at least two inlets, feeding an excipient to the other of the at least two inlets, mixing the material stream comprising the API and the excipient in the at least one mixing unit, measuring parameters of the contents of the material stream with the at least one analytical sensor upstream of the tablet press, controlling the two inlets and/or the mixing unit in response to the parameters measured, continuously supplying the tablet press with the material stream, controlling the speed of the tablet press in response to the parameters measured upstream of the tablet press, and discharging tablets at the at least one outlet.

Abstract: The contained module (1) comprises inlets for an active pharmaceutical ingredient (API) and for an excipient. The inlets are in fluid communication with at least one mixing unit (41,46), and the outlet of the tablet press (6) is in fluid communication with the releasable outlet port for tablets. The material stream comprising the API and the excipient is mixed in the mixing units. During operation parameters of the contents of the material stream are measured with one or more analytical sensors upstream of the tablet press. The speed of the tablet press is controlled in response to the parameters measured upstream of the tablet press. The finished tablets are discharged at an outlet of the tablet press (6).